Jia L, Peng J, Sun N, Chen H, et al. Effect of PR status on the prognosis of advanced ER-high HER2-negative breast cancer patients receiving CDK4/6 inhibitor combined with endocrine as first-line therapy. BMC Cancer 2024;24:850.
PMID: 39020297